Pivotal phase III trials in advanced breast cancer, where CDK4/6 inhibitors were administered in combination with endocrine therapy (e.g., aromatase inhibitor, fulvestrant), have revealed that palbociclib, ribociclib and abemaciclib were generally well tolerated. This evidence concerns the gene CYP19A1 and breast cancer.